BridgeMD
Sodium-glucose cotransporter-2 inhibitors to stabilize coronary ather-osclerosis progression after acute myocardial infarction in women and men with diabetes mellitus
EU CTIS ID: 2025-523375-29-00
What this study is testing
To evaluate the effect of SGLT2i on coronary atheroscle-rosis progression on native (untreated) coronary segments in diabetic patients after an AMI treated with successful PCI.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥18 years
- Established diagnosis of non-insulin-dependent diabetes mellitus
- Hospital admission for AMI (with or without ST-segment elevation); AMI diagnosis should be confirmed with a troponin measurement according to the Fourth Universal Definition of Myocardial Infarction
- Successful PCI
- Complete revascularization obtained within the index hospitalization
- Ability to provide informed consent
You likely can't join if
- Known intolerance/contraindications to SGLT2i therapy
- Ongoing treatment with SGLT2i at the time of AMI
- Contraindications to undergo CCTA
- Insulin-dependent diabetes mellitus
- Incomplete revascularization with indication to staged PCI on non-culprit lesions
- Left ventricular ejection fraction <35% prior to discharge
See the full eligibility criteria
- Age ≥18 years
- Established diagnosis of non-insulin-dependent diabetes mellitus
- Hospital admission for AMI (with or without ST-segment elevation); AMI diagnosis should be confirmed with a troponin measurement according to the Fourth Universal Definition of Myocardial Infarction
- Successful PCI
- Complete revascularization obtained within the index hospitalization
- Ability to provide informed consent
- Known intolerance/contraindications to SGLT2i therapy
- Ongoing treatment with SGLT2i at the time of AMI
- Contraindications to undergo CCTA
- Insulin-dependent diabetes mellitus
- Incomplete revascularization with indication to staged PCI on non-culprit lesions
- Left ventricular ejection fraction <35% prior to discharge
- Known allergy to aspirin or ticagrelor
- Known pregnancy
- Life expectancy <1 year for non-cardiac conditions
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.